Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
出版年份 2018 全文链接
标题
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation
作者
关键词
-
出版物
ANNALS OF HEMATOLOGY
Volume 97, Issue 12, Pages 2269-2278
出版商
Springer Nature America, Inc
发表日期
2018-10-12
DOI
10.1007/s00277-018-3503-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
- (2016) Mohamed A. Kharfan-Dabaja et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis
- (2016) S. A. Parikh et al. BLOOD
- The clinical implications of gene mutations in chronic lymphocytic leukaemia
- (2016) Davide Rossi et al. BRITISH JOURNAL OF CANCER
- Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
- (2016) Emili Montserrat et al. Clinical Lymphoma Myeloma & Leukemia
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy
- (2016) Roxanne C. Jewell et al. LEUKEMIA & LYMPHOMA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostication of chronic lymphocytic leukemia in the era of new agents
- (2016) B. Eichhorst et al. Hematology-American Society of Hematology Education Program
- Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
- (2015) Michael Hallek AMERICAN JOURNAL OF HEMATOLOGY
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
- (2015) Erick Xavier et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Initial treatment of CLL: integrating biology and functional status
- (2015) N. Jain et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model
- (2015) Stefano Molica et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies
- (2014) Mary Eapen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
- (2014) N. Pflug et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- CD49d Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia
- (2014) Pietro Bulian et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice
- (2013) Francesco Zaja et al. AMERICAN JOURNAL OF HEMATOLOGY
- Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis
- (2013) Patricia T. Greipp et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical implications of the molecular genetics of chronic lymphocytic leukemia
- (2013) R. Foa et al. HAEMATOLOGICA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
- (2012) Andrew R. Pettitt et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining the prognosis of early stage chronic lymphocytic leukaemia patients
- (2011) Chris Pepper et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia
- (2011) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia
- (2011) Martina Seiffert et al. LEUKEMIA & LYMPHOMA
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
- (2009) Apostolia-Maria Tsimberidou et al. CANCER
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Chronic lymphocytic leukaemia
- (2008) G Dighiero et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started